At a glance
ClinicalIndex Comparison RecordPhase 2Active· 7 enrolled
Drug / intervention
Letetresgene autoleucel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
In Brief
A Phase 2 clinical trial evaluating Letetresgene autoleucel, Cyclophosphamide, and 1 other intervention for Neoplasms. Active but no longer recruiting, targeting 7 participants across 38 sites in 7 countries.
Detailed Summary
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesCanada, France, Italy, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2ActiveOverdue
2020202120222023202420252026
Enrollment StartDec 2019
Primary CompletionOct 2022
First PostedAug 2023
Study CompletionJul 2026
TodayJul 2026
First PostedAug 15, 2023
Enrollment StartDec 31, 2019
Primary CompletionOct 12, 2022
Study CompletionJul 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 2.9 years ago
Interventions
Letetresgene autoleuceldrug
Letetresgene autoleucel will be administered.
Cyclophosphamidedrug
Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Fludarabinedrug
Fludarabine will be used as a lymphodepleting chemotherapy.